Consolidated Financial Results for the Nine Months Ended September 30, 2025 (Under IFRS)11/14TDnetPDF(351KB)
Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2025)8/15TDnetPDF(523KB)
Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2025 (under IFRS)8/13TDnetPDF(344KB)
Licensing Agreement for DARVIAS and episil in Southeast Asia, Oceania, Middle East, and Africa Regions, Sales Approval for episil in Singapore8/12TDnetPDF(203KB)